I should have given this update sooner. I met management following the results. Most of it was usual running of business detail, but a couple of relevant things did come up;
Australia - Sad to say but don't expect any price updates here. GW are still using a pricing model that was put in place c.20 years ago. If they were to update to current currency rates, it would have a significant cash cost associated with it (warehousing and other costs, estimated at c. £5m cost) which management don't feel is worth it considering the addressable market in Aus, would rather be investing that cash into new growing markets.
TV Shows - Sounds like they have been getting approaches for licencing rights for years, but the offers have not been financially attractive. By the tone of things, production companies are more willing to give GW better deals which is why we are now seeing various media offerings appear.
Sylvaneth Release Delay - Shipping to the US was the issue behind this. When GW product gets sent over from the UK is goes in containers with other related products (model trees from third party producers were the example given). These third party products were held at customs for tariff related reasons, though they held entire container contents until resolution, hence the delay. Management consider this to be a one off and don't expect any other issues.